Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.10 +2.2%	$3.74	$2.12 ▼ $5.80	$408.75M	1.99	1.51 million shs	5.66 million shs
HUMA Humacyte	$1.88 +5.4%	$2.34	$1.15 ▼ $7.48	$291.16M	1.9	3.99 million shs	6.05 million shs
MGNX MacroGenics	$1.62 -2.7%	$1.51	$0.99 ▼ $5.10	$101.89M	1.65	920,287 shs	474,492 shs
YMAB Y-mAbs Therapeutics	$8.52 +0.1%	$5.16	$3.55 ▼ $16.11	$386.92M	0.57	488,611 shs	1.25 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+6.08%	+0.50%	-0.50%	+68.49%	+2.30%
HUMA Humacyte	-0.84%	-19.46%	-27.94%	-5.82%	-73.23%
MGNX MacroGenics	+12.93%	+3.11%	+5.06%	+7.79%	-52.97%
YMAB Y-mAbs Therapeutics	0.00%	-0.12%	+95.18%	+120.47%	-21.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.0543 of 5 stars	3.5	3.0	0.0	3.0	0.0	0.0
HUMA Humacyte	1.9494 of 5 stars	3.5	2.0	0.0	1.7	0.8	0.6
MGNX MacroGenics	4.3456 of 5 stars	3.3	3.0	4.4	3.0	2.5	0.6
YMAB Y-mAbs Therapeutics	2.7013 of 5 stars	2.9	4.0	0.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	147.45% Upside
HUMA Humacyte	3.00	Buy	$10.64	467.01% Upside
MGNX MacroGenics	2.57	Moderate Buy	$5.40	234.37% Upside
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	13.00% Upside

Current Analyst Ratings Breakdown

Latest MGNX, AQST, YMAB, and HUMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	7.10	N/A	N/A	($0.73) per share	-5.62
HUMA Humacyte	$818K	355.94	N/A	N/A	$0.03 per share	62.57
MGNX MacroGenics	$152.43M	0.67	N/A	N/A	$1.85 per share	0.87
YMAB Y-mAbs Therapeutics	$87.68M	4.41	N/A	N/A	$1.93 per share	4.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	N/A
HUMA Humacyte	-$148.70M	-$0.45	N/A	N/A	N/A	N/A	N/A	-78.26%	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/19/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	N/A

Latest MGNX, AQST, YMAB, and HUMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MGNX MacroGenics	-$0.59	-$0.57	+$0.02	-$0.57	$28.06 million	N/A
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	4.48
HUMA Humacyte	2.97	2.45	3.28
MGNX MacroGenics	N/A	3.28	3.11
YMAB Y-mAbs Therapeutics	N/A	4.00	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
HUMA Humacyte	44.71%
MGNX MacroGenics	96.89%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
HUMA Humacyte	5.10%
MGNX MacroGenics	13.00%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.03 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

MGNX, AQST, YMAB, and HUMA Headlines

Recent News About These Companies

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13 at 2:17 AM | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11 at 8:40 AM | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given Neutral Rating at HC Wainwright

August 8, 2025 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial

August 8, 2025 | americanbankingnews.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)

August 7, 2025 | msn.com

SERB bets on rare cancer drug in $412 million deal for Y-mAbs

August 6, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, AQST, YMAB, and HUMA Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.10 +0.09 (+2.22%)

Closing price 03:59 PM Eastern

Extended Trading

$4.11 +0.01 (+0.27%)

As of 04:10 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Humacyte NASDAQ:HUMA

$1.88 +0.10 (+5.45%)

Closing price 03:59 PM Eastern

Extended Trading

$1.88 +0.01 (+0.43%)

As of 04:16 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

MacroGenics NASDAQ:MGNX

$1.62 -0.05 (-2.71%)

Closing price 03:58 PM Eastern

Extended Trading

$1.62 0.00 (0.00%)

As of 04:10 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.52 +0.01 (+0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$8.52 0.00 (0.00%)

As of 04:10 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time